Herpes Simplex Virus 2 (IgG), with Reflex to HSV-2 Inhibition

17170

LAB508

If Herpes Simplex Virus 2 (IgG) >1.09, then HSV-2 Inhibition Study will be performed at an additional charge (CPT code(s): 86696).

1 mL serum

0.7 mL

Transport tube

Room temperature

Room temperature: 7 days
Refrigerated: 14 days
Frozen: 30 days

Gross hemolysis • Grossly lipemic • Plasma

Tues, thurs, sat

2-5 days

Individuals infected with HSV may not exhibit detectable IgG antibody in the early stages of infection.

Index	Interpretation
<0.90	Negative
0.90-1.09	Equivocal
>1.09	Positive

This assay utilizes recombinant type-specific antigens to differentiate HSV-1 from HSV-2 infections. A index positive result cannot distinguish between recent and past infection. If recent HSV infection is suspected but the results are negative or equivocal, the assay should be repeated in 4-6 weeks. The performance index characteristics of the assay have not been established for pediatric populations, immunocompromised patients, or neonatal screening.

Herpes Simplex Virus (HSV) is responsible for several clinically significant human viral diseases, with severity ranging from inapparent to fatal. Clinical manifestations include genital tract infections, neonatal herpes, meningoencephalitis, keratoconjunctivitis, and gingivostomatitis. There are two HSV serotypes that are closely related antigenically. HSV type 2 is more commonly associated with genital tract and neonatal infections, while HSV type 1 is more commonly associated with infections of non-genital sites. Specific typing is not usually required for diagnosis or treatment. The mean time to seroconversion using the type specific assay is 25 days. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, or for testing of immunocompromised patients.